查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1518478

真实世界证据解决方案市场 - 组件（服务、数据集）、应用程式（药物开发和批准、上市后监督）收入模型（订阅、按使用付费）、部署模型、最终用户和预测 2024 - 2032 年

Real World Evidence Solutions Market - Component (Services, Data sets), Application (Drug Development and Approvals, Post-Market Surveillance) Revenue Model (Subscription, Pay per use), Deployment Model, End User & Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在慢性病盛行率不断上升的推动下，真实世界证据解决方案市场规模在 2024 年至 2032 年期间将以 15.7% 的复合年增长率扩大。根据 CDC 的资料，每年有超过 934,500 名美国人死于心臟病或中风，占死亡人数的四分之一以上。 170 万人被诊断出罹患癌症，导致超过 60 万人死亡。此外，超过 3,800 万美国人患有糖尿病，9,800 万成年人患有糖尿病前期。

现实世界的证据在理解现实世界中的疾病模式、治疗结果和患者管理实践方面发挥着至关重要的作用。透过分析来自不同来源（包括电子健康记录（EHR）和患者登记）的大规模资料集，利害关係人可以识别趋势、评估治疗效果并制定有针对性的干预措施以改善患者的治疗结果。将 RWE 融入临床研究和医疗保健服务对于解决慢性病带来的复杂挑战和有效优化医疗保健资源至关重要。此外，个人化医疗和以患者为中心的护理的趋势将扩大市场前景。

现实世界的证据解决方案产业根据组件、应用程式、收入模型、部署模型、最终用户和区域进行分类。

到 2032 年，上市后监测领域将快速成长。 PMS 利用真实资料来侦测不良事件、评估产品效能并确保法规遵循。透过利用 RWE 解决方案，医疗保健利害关係人可以进行全面的监测活动，及早发现潜在的安全问题，并实施必要的干预措施来保护病患健康。

到 2032 年，资料集组件细分市场资料将资料激增。透过汇总和分析这些资料集，利害关係人可以全面了解现实世界中的疾病模式、治疗效果和患者结果。先进的资料整合和互通性解决方案有助于协调不同的资料集，从而实现医疗保健组织和研究机构的无缝分析和决策。

在强大的医疗基础设施、支持性监管环境以及数位医疗技术日益普及的推动下，欧洲现实世界证据解决方案产业将在 2032 年之前稳步增长。欧洲药品管理局（EMA）和各国监管机构鼓励在监管决策中使用RWE，进一步刺激市场成长。此外，欧洲学术机构、医疗保健提供者和製药公司之间的合作正在促进基于 RWE 的研究计划和临床试验的发展，从而增加市场价值。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 越来越关注加速药物开发和降低成本
      • 药品和医疗器材即时安全性和有效性监测的需求不断增长
      • 越来越多地采用 RWE 解决方案来做出明智的报销决策
      • 在临床决策中越来越多地采用资料分析服务
    • 产业陷阱与挑战
      • 现实世界资料的整合和互通性缺乏标准化
      • 缺乏熟练的专业人员
  • 成长潜力分析
  • 技术景观
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按组成部分，2021 - 2032 年

  • 主要趋势
  • 服务
  • 数据集
    • 不同的资料集
      • 临床设置资料集
      • 索赔资料集
      • 药房资料集
      • 患者供电的资料集
      • 基于註册表的资料集
    • 综合资料集

第 6 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 药物开发和批准
    • 肿瘤学
    • 心血管疾病
    • 神经病学
    • 免疫学
    • 其他治疗领域
  • 医疗器材开发和核准
  • 上市后监督
  • 市场准入和报销/覆盖决策
  • 临床和监管决策

第 7 章：市场估计与预测：按收入模式，2021 - 2032

  • 主要趋势
  • 按使用付费（基于价值的定价）
  • 订阅

第 8 章：市场估计与预测：按部署模型，2021 - 2032

  • 主要趋势
  • 本地部署
  • 基于云端

第 9 章：市场估计与预测：按最终用户划分，2021 - 2032 年

  • 主要趋势
  • 製药和医疗器材公司
  • 医疗保健付款人
  • 医疗保健机构
  • 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 阿联酋
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 11 章：公司简介

  • Aetion, Inc.
  • Cognizant Technology Solutions Corporation
  • Elevance Health, Inc.
  • Fortrea Inc.
  • ICON plc.
  • IQVIA Holdings Inc.
  • Merative
  • Optum, Inc.
  • Oracle Corporation
  • Parexel International Corporation
  • PerkinElmer Inc.
  • SAS Institute Inc.
  • Syneos Health, Inc.
  • Thermo Fisher Scientific Inc.
  • TriNetX LLC
简介目录
Product Code: 9187

The Real-World Evidence Solutions Market size will expand at 15.7% CAGR during 2024-2032, driven by the increasing prevalence of chronic diseases. According to the CDC data, annually, over 934,500 Americans die from heart disease or stroke, representing more than one in four deaths. While cancer is diagnosed in 1.7 million people, with over 600,000 fatalities. Additionally, more than 38 million Americans have diabetes, and 98 million adults have prediabetes.

Real world evidence plays a crucial role in understanding disease patterns, treatment outcomes, and patient management practices in real-world settings. By analyzing large-scale data sets from diverse sources, including electronic health records (EHRs) and patient registries, stakeholders can identify trends, assess treatment effectiveness, and develop targeted interventions to improve patient outcomes. The integration of RWE into clinical research and healthcare delivery is essential for addressing the complex challenges posed by chronic diseases and optimizing healthcare resources efficiently. Further, the trend of personalized medicine and patient-centric care will augment the market outlook.

The real-world evidence solutions industry is classified based on component, application, revenue model, deployment model, end-user, and region.

The post-market surveillance segment will grow rapidly through 2032. The post-market surveillance (PMS) involves monitoring the efficacy of medical products after they have been approved. PMS utilizes real-world data to detect adverse events, assess product performance, and ensure regulatory compliance. By leveraging RWE solutions, healthcare stakeholders can conduct comprehensive surveillance activities, identify potential safety concerns early, and implement necessary interventions to protect patient health.

The data sets component segment share will record notable surge by 2032. The data sets encompass diverse sources such as electronic health records (EHRs), claims data, patient registries, and wearable devices. By aggregating and analyzing these data sets, stakeholders can derive comprehensive insights into disease patterns, treatment effectiveness, and patient outcomes in real-world settings. Advanced data integration and interoperability solutions facilitate the harmonization of disparate data sets, enabling seamless analysis and decision-making across healthcare organizations and research institutions.

Europe real world evidence solutions industry will grow at a steady pace through 2032, driven by a robust healthcare infrastructure, supportive regulatory environment, and increasing adoption of digital health technologies. The European Medicines Agency (EMA) and national regulatory authorities encourage the use of RWE in regulatory decision-making, further stimulating market growth. Additionally, collaborations between academic institutions, healthcare providers, and pharmaceutical companies in Europe are promoting the development of RWE-based research initiatives and clinical trials, adding to market value.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing focus towards accelerating drug development and cost reduction
      • 3.2.1.2 Growing demand for real-time safety and efficacy monitoring of drugs and medical devices
      • 3.2.1.3 Increasing adoption of RWE Solutions for informed reimbursement decision-making
      • 3.2.1.4 Increasing adoption of data analytics services in clinical decision making
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Lack of standardization in integration and interoperability of real-world data
      • 3.2.2.2 Shortage of skilled professionals
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Services
  • 5.3 Data sets
    • 5.3.1 Disparate data sets
      • 5.3.1.1 Clinical settings data sets
      • 5.3.1.2 Claims data sets
      • 5.3.1.3 Pharmacy data sets
      • 5.3.1.4 Patient powered data sets
      • 5.3.1.5 Registry-based data sets
    • 5.3.2 Integrated data sets

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Drug development and approvals
    • 6.2.1 Oncology
    • 6.2.2 Cardiovascular disease
    • 6.2.3 Neurology
    • 6.2.4 Immunology
    • 6.2.5 Other therapeutic areas
  • 6.3 Medical device development and approvals
  • 6.4 Post-market surveillance
  • 6.5 Market access & reimbursement/coverage decision-making
  • 6.6 Clinical & regulatory decision-making

Chapter 7 Market Estimates and Forecast, By Revenue Model, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pay-per-use (value-based pricing)
  • 7.3 Subscription

Chapter 8 Market Estimates and Forecast, By Deployment Model, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 On-premise
  • 8.3 Cloud-based

Chapter 9 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Pharmaceutical and medical device companies
  • 9.3 Healthcare payers
  • 9.4 Healthcare providers
  • 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends, by region
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 South Korea
    • 10.4.5 Australia
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 UAE
    • 10.6.3 Saudi Arabia
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Aetion, Inc.
  • 11.2 Cognizant Technology Solutions Corporation
  • 11.3 Elevance Health, Inc.
  • 11.4 Fortrea Inc.
  • 11.5 ICON plc.
  • 11.6 IQVIA Holdings Inc.
  • 11.7 Merative
  • 11.8 Optum, Inc.
  • 11.9 Oracle Corporation
  • 11.10 Parexel International Corporation
  • 11.11 PerkinElmer Inc.
  • 11.12 SAS Institute Inc.
  • 11.13 Syneos Health, Inc.
  • 11.14 Thermo Fisher Scientific Inc.
  • 11.15 TriNetX LLC